A Randomised, Cross-over Study to Evaluate Efficacy and Tolerability of FLX-787 in Patients with Multiple Sclerosis spasticity and spasms/cramps

Trial Profile

A Randomised, Cross-over Study to Evaluate Efficacy and Tolerability of FLX-787 in Patients with Multiple Sclerosis spasticity and spasms/cramps

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs FLX 787 (Primary)
  • Indications Cramp; Multiple sclerosis; Spasm
  • Focus Therapeutic Use
  • Acronyms Flex201
  • Sponsors Flex Pharma
  • Most Recent Events

    • 19 Jan 2017 Prortocol amendment as per Australian New Zealand Clinical Trials Registry;washout period extended,enrollment ctiteria added,and patient number changed to 80
    • 19 Jan 2017 Planned number of patients changed from 50 to 80.
    • 28 Jun 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top